UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
After budgeting mistakes, there are various ways to save. Discover actionable tips to help you recover and enhance your financial health.
20,093 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
A major family-office investor has increased its position in Middleby as the company prepares a spin-off. This move o...
Major cryptocurrencies hold support as regulatory and macro headlines shape momentum. The crypto price prediction tod...
A high-profile insider move at Navan has investors weighing the stock. This guide breaks down what navan's chief acco...
AI-driven demand and easing supply bottlenecks push chipmakers into the spotlight. Here’s a timely look at the best s...
Bitcoin surged past $74,000 as institutional buying returned to the market, sparking a wider crypto rally. Investors ...
Microsoft is raising Copilot prices in its top enterprise plan, signaling a major AI monetization push. This deep div...
Cruise investors wrestle with Carnival earnings anxiety: good, the push-pull between sunny passenger demand and risin...
Insider trading activity can reveal how executives view their company’s future. This article digs into a real-world c...
Disney has canceled the upcoming 22nd season of The Bachelorette, three days before its premiere, amid a resurfaced v...
Kevin O’Leary’s $4.2 billion Softkey exit in 1999 turned him into a millionaire, but the moment was surprisingly low-...
With earnings on the horizon and a bold pivot to AI infrastructure, investors face a tough call. This guide breaks do...